ペグビソマント
(October 2009). doi:10.1186/1472-6823-9-20. PMC 2768727. PMID 19814797. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727/.
↑ “Discovery and mechanism of action of pegvisomant”. European Journal of Endocrinology 148 Suppl 2: S21-5. (April 2003). doi:10.1530/eje.0.148s021. PMID 12670297.
↑ “Discovery and uses of pegvisomant: a growth hormone antagonist”. Endokrynologia Polska 58 (4): 322–9. (2007). PMID 18058724.
↑ CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.) (PDF) (Report). Canadian Agency for Drugs and Technologies in Health.